omniture

Biostar Pharmaceuticals' CEO Visits the United States as a Representative of President Hu Jintao's Delegation

2011-01-20 12:31 6529

XIANYANG, China, Jan. 20, 2011 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety of pharmaceutical products, today announced that its Chairman and Chief Executive Officer, Mr. Ronghua Wang, is a Chinese Entrepreneur Representative on Chinese President Hu Jintao's delegation during the official visit to the United States in January 2011. The Sino-U.S. summit is a forum focused on China-U.S. trade and economic cooperation.

As a member of President Hu's economic advisory group, Mr. Wang will serve as the representative of medicine.  During the state visit, from January 18th to 23rd, Mr. Wang will give presentations at various joint conferences to be held by both the U.S. and Chinese government officials with the goal of identifying new partnerships in the U.S.

"I am deeply honored to be invited to serve as the representative of medicine on President Hu's economic advisory group for this important summit," said Mr. Wang. "I look forward to contributing to the economic discussions between our two nations and the opportunity to promote greater awareness of the rapidly growing Chinese pharmaceutical market. This affirms Biostar's growing position as a recognized player in this important industry."

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar currently manufactures two broad-based OTC products, two prescription-based pharmaceuticals, one medical device and five health supplements.

Cautionary Note about Forward Looking Statements

This press release contains forward-looking statements which fall within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or words of similar meaning. They may also use words such as, "would," "should," "could" or "may." Factors that may cause our actual results to differ materially from those described in forward-looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our operations and investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of sales and profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to continue our expansion in the rural areas, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, and other subsequent public filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Biostar disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

   For further information, contact:

 

 

 

 

 

 

    Bill Chen (Deyin), CFO

 

 

 

    Tel: +86-138-161-00700

 

 

 

    Email: bchen65@gmail.com    

 

 

 

 

 

 

    Ted Haberfield

 

 

 

    HC International, Inc.

 

 

 

    Tel: US +1-760-755-2716

 

 

 

    Email: thaberfield@hcinternational.net

 

 

 

    Web: http://www.hcinternational.net

 

 

 

 

 
Source: Biostar Pharmaceuticals, Inc.
Related Stocks:
NASDAQ:BSPM
collection